On October 12, 2025 Incyte (Nasdaq:INCY) reported that results from Phase 1 proof-of-concept studies of INCA33890, a promising TGFβR2×PD-1-directed bispecific antibody, and INCB161734, a novel, selective and orally bioavailable KRAS G12D inhibitor, will be highlighted as oral presentations at the upcoming European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2025 in Berlin (Press release, Incyte, OCT 12, 2025, View Source [SID1234656567]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are encouraged by the positive findings being presented with our TGFβR2×PD-1 and KRAS G12D inhibitor programs, which validate our rationale for advancing the development of these novel investigational compounds," said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. "There remains a significant need for new treatment options for patients with advanced solid tumors like colorectal cancer and pancreatic ductal adenocarcinoma and we look forward to providing updates on these clinical development programs."
Details on INCA33890 and INCB161734 oral presentations at ESMO (Free ESMO Whitepaper) include:
INCA33890 (PD-1/TGFβR2)
A Phase 1 Study Of INCA33890, A PD-1/TGFβR2 Bispecific Antibody, For Advanced Solid Tumours
(Session Title: Mini oral session: Investigational immunotherapy. [October 17, 8:00 – 9:30 a.m. ET [2:00 – 3:30 p.m. CEST]. Abstract #1522.)
INCB161734 (KRAS G12D)
Preliminary Phase 1 Results Of INCB161734, A Novel Oral KRAS G12D Inhibitor, In Patients With Advanced Or Metastatic Solid Tumors
(Session Title: Proffered paper session: Developmental therapeutics. [October 19, 8:45 – 10:20 a.m. ET [2:45 – 4:20 p.m. CEST]. Abstract #916O.)
Analyst Event and Webcast
The data from the ESMO (Free ESMO Whitepaper) oral presentations and additional results from the INCA33890 in patients with microsatellite stable (MSS) colorectal cancer and INCB161734 in pancreatic ductal adenocarcinoma (PDAC) will also be discussed at an in-person analyst and investor event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. ET (7:30 – 9:00 p.m. CEST) at ESMO (Free ESMO Whitepaper).
The event will be webcasted and can be accessed via the Events and Presentations tab of the Investor section of Incyte.com and it will be available for replay for 30 days.
More information regarding the 2025 ESMO (Free ESMO Whitepaper) Congress can be found at: View Source